The medical hashish industries in Australia and New Zealand are persevering with to evolve quickly, with each markets displaying indicators of maturation, regulatory recalibration, and increasing export ambitions, in line with new information.
Drawing on findings from Prohibition Companions’ Australia & New Zealand Hashish Knowledge Pack, produced in collaboration with Cannabiz, the most recent evaluation highlights diverging however complementary developments throughout the 2 nations. Australia stays the biggest medical hashish market outdoors the US, whereas New Zealand continues to refine its evidence-based, export-oriented medical mannequin.
Australia: Regulation meets fast development
Australia’s medical hashish market is about to surpass AUD$1 billion in gross sales by the top of 2025, underlining its place as a worldwide chief in medical hashish outdoors North America. Progress has been pushed by telehealth prescribing, widespread product availability, and the proliferation of specialized clinics.
New insights gleaned from the Knowledge Pack recommend that Australia’s medical hashish market continues to be led by high-THC merchandise, which account for almost all of each prescription quantity and whole gross sales worth.
The info exhibits that dried-flower codecs and inhalable merchandise have seen the strongest development by 2023 and 2024, reflecting the preferences of each sufferers and prescribers for fast-acting supply strategies.
October 7, 2025
No Feedback
Inside oil-based classes, CBD and balanced formulations preserve a constant share, notably amongst sufferers looking for non-intoxicating choices or long-term symptom administration. Nonetheless, the general market trajectory exhibits that THC-dominant merchandise now underpin the majority of economic exercise.
Pricing stays comparatively steady throughout product sorts, and whole class values level to sustained double-digit development over the previous 12 months.
Nonetheless, the tempo of growth has prompted a federal evaluation of the Therapeutic Items Administration (TGA) framework. Areas beneath scrutiny embody product promoting, prescribing pathways, and high quality oversight. The evaluation follows public session concluded in October 2025, with regulatory adjustments anticipated to tighten controls on unapproved merchandise and telehealth prescribing.
Regardless of ongoing import reliance, primarily from Canada, home manufacturing is increasing. Forty licensed cultivators produced 41 tonnes in 2024, up from 25 tonnes the earlier 12 months. Australia’s export footprint can be rising, notably into Germany, the place outbound volumes are anticipated to double in 2025.
Insights from regional market information
The detailed datasets behind these findings, together with breakdowns by product format, cannabinoid ratio, and period-on-period development, can be found by Prohibition Companions’ Australia & New Zealand Hashish Knowledge Pack, a part of the organisation’s wider sequence monitoring hashish markets throughout the Asia-Pacific area, offering complete protection of the Australia and New Zealand hashish markets by to 2029.
Throughout each markets, the developments level to growing normalisation of medical hashish prescribing, rising affected person consciousness, and stronger regulatory oversight. For stakeholders trying to assess market efficiency or establish rising alternatives, data-led evaluation is now central to understanding regional dynamics.
The submit Excessive-THC Leads Progress as Australia Tightens TGA Prescribing Guidelines appeared first on Enterprise of Hashish.
